Method for detecting content of poloxamer 407

By using ammonium formate aqueous solution as mobile phase in high performance liquid chromatography, the problems of peak shape difference and separation difficulties in Poloxamer 407 detection are solved, and stable and controllable detection results and cost reduction are achieved, which meets the detection Multiple performance requirements.

CN118937548APending Publication Date: 2024-11-12JIANGSU SHENMING MEDICAL TECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310516797.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-09
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, the detection method of Poloxamer 407 has peak shape difference, frontier or tailing phenomena, and is difficult to effectively separate from other components, making it impossible to achieve stable and controllable measurements.

Method used

The water ammonium formate solution was used as the mobile phase, combined with high performance liquid chromatography and isometric elution, and the flow rate and concentration of the mobile phase were 0.25-0.75 mL/min and 95-105 mmol/L. The column temperature is 20-30°C to achieve effective detection of Poloxamer 407.

Benefits of technology

The stable and controllable measurement of the content of Poloxamer 407 is achieved, and the peak shape is obtained, which reduces the detection cost, and meets the specificity of the detection, system applicability, quantitative limit, linearity, repeatability, intermediate precision, Accuracy, durability and stability requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937548A_ABST
    Figure CN118937548A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting the content of poloxamer 407. The detection method comprises the following steps: detecting a to-be-detected sample solution through high performance liquid chromatography, and calculating the content, wherein the sample solution to be detected contains poloxamer 407; in the high performance liquid chromatography, a chromatographic column is a gel chromatographic column, and an isocratic elution mode is adopted; the mobile phase is an ammonium formate aqueous solution. The detection method provided by the invention can realize stable and controllable measurement of the content of poloxamer 407, and a better peak shape is obtained; the specificity, the system applicability, the quantitation limit, the linearity and range, the repeatability, the intermediate precision, the accuracy, the durability and the stability are good, and the detection requirements are met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for detecting the content of poloxamer 407. Background Art

[0002] Poloxamer is a block copolymer of polyoxyethylene and polyoxypropylene, a non-ionic surfactant, and a common polymer pharmaceutical excipient, mainly used as a solubilizer and emulsifier in pharmaceutical preparations. So far, the analysis methods of poloxamer mainly include colorimetry, radiolabeling, and size exclusion chromatography, among which size exclusion chromatography, also known as gel permeation chromatography, is mainly used for the separation of macromolecular substances.

[0003] However, when the poloxamer detection method in the prior art is used for poloxamer 407, not only the peak shape is poor, but also it is impossible to effectively separate it from other components. Therefore, it is necessary to design an effective detection method for the content of poloxamer 407. Summary of the invention

[0004] The technical problem to be solved by the present invention is to overcome the defects of poor peak shape and front or tailing phenomenon when detecting the content of poloxamer 407 in the prior art, and provide a method for detecting the content of poloxamer 407. The detection method of the present invention can realize stable and controllable measurement of the content of poloxamer 407 and obtain a better peak shape; its specificity, system applicability, quantitative limit, linearity and range, repeatability, intermediate precision, accuracy, durability and stability are all good, meeting the detection requirements.

[0005] The present invention solves the technical problem through the following technical solutions.

[0006] In the process of studying the detection of poloxamer 407 content, the inventors found that the choice of mobile phase has a great influence on the effect. If "buffer salt: acetonitrile" or "buffer salt: methanol" is used as the mobile phase, the peak shape in the detection result is poor, with a front or tail, and if there are many other components in the solution, it is difficult to achieve effective separation. The inventors creatively found that if an aqueous solution of ammonium formate is used as the mobile phase and an isocratic elution method is used, combined with other technical features, not only can poloxamer 407 be effectively detected, but also the detection cost can be reduced.

[0007] The present invention provides a method for detecting the content of poloxamer 407, which comprises the following steps: detecting a sample solution to be tested by high performance liquid chromatography and calculating the content;

[0008] Wherein, the sample solution to be tested contains poloxamer 407;

[0009] In the high performance liquid chromatography method: the chromatographic column is a gel chromatographic column, an isocratic elution method is adopted; and the mobile phase is an ammonium formate aqueous solution.

[0010] In the present invention, the concentration of poloxamer 407 in the sample solution to be tested may be 0.5-1.5 mg / mL, for example, 1 mg / mL.

[0011] In the present invention, preferably, the sample solution to be tested is prepared by dissolving the component to be tested in a diluent.

[0012] Wherein, the diluent may be water.

[0013] In the present invention, the sample solution to be tested may also include sodium alginate. When the medicament contains both poloxamer and sodium alginate, the traditional detection method (such as "buffer salt-organic solvent" as mobile phase) is difficult to achieve effective separation, which increases the difficulty of detection. The detection method of the present invention can well avoid the above problems. In the sample solution to be tested, the component to be tested may be an embolic agent, and the embolic agent also includes sodium alginate.

[0014] Wherein, in the embolic agent, the mass ratio of the poloxamer 407 to the sodium alginate may be (10-35):(0-1).

[0015] In the present invention, in the high performance liquid chromatography method, the flow rate of the mobile phase can be conventional in the art, preferably 0.25 to 0.75 mL / min, such as 0.5 mL / min.

[0016] In the present invention, in the high performance liquid chromatography method, the concentration of ammonium formate in the ammonium formate aqueous solution may be 95 to 105 mmol / L, for example, 100 mmol / L.

[0017] In the present invention, the injection volume of the high performance liquid chromatography method can be conventional in the art, preferably 5 to 20 μL, such as 10 μL.

[0018] In the present invention, in the high performance liquid chromatography, the particle size of the filler in the chromatographic column is 8 to 12 μm, for example, 10 μm.

[0019] In the present invention, in the high performance liquid chromatography, the column temperature can be room temperature, preferably 20-30°C, for example 25°C.

[0020] In the present invention, in the high performance liquid chromatography method, the chromatographic column can be a Shodex OHpak SB-804HQ chromatographic column.

[0021] In the present invention, in the high performance liquid chromatography method, the length of the chromatographic column can be 200 to 500 mm, for example, 300 mm.

[0022] In the present invention, in the high performance liquid chromatography method, the inner diameter of the chromatographic column may be 5 to 10 mm, for example, 8 mm.

[0023] In the present invention, in the high performance liquid chromatography, the detector may be an evaporative light scattering detector.

[0024] In the present invention, in the high performance liquid chromatography, the temperature of the drift tube in the detector can be 48-52°C, for example 50°C.

[0025] In the present invention, the method for determining the content can be a standard curve method.

[0026] In the present invention, the standard curve method refers to using a pure product of the component to be tested, poloxamer 407, as a reference substance, dissolved in a diluent to prepare a linear series solution, injecting equal volumes under the same chromatographic conditions, measuring the peak area or peak height, using the peak area or peak height to plot a standard curve against the concentration, obtaining a linear equation, and then calculating the concentration of the component to be tested in the test solution through the linear equation and the peak area or peak height of the component to be tested in the test solution.

[0027] Wherein, the diluent may be water.

[0028] Wherein, the concentrations of the linear series solutions may be 0.8 mg / mL, 1.0 mg / mL and 1.2 mg / mL.

[0029] Among them, the linear equation obtained by the standard curve method can be "y=1.9326x+0.5495 (r=0.9999)", "y=1.9802x+0.5632 (r=1.0000)" or "y=1.9915x+0.519 (r=0.9992)", wherein x is the logarithm of concentration (μg / mL) and y is the logarithm of peak area.

[0030] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.

[0031] The reagents and raw materials used in the present invention are commercially available.

[0032] The positive and progressive effects of the present invention are:

[0033] (1) The content detection method provided by the present invention can achieve stable and controllable measurement of the content of poloxamer 407, obtain a better peak shape, and reduce the detection cost; by investigating and verifying the specificity, system applicability, quantitative limit, linearity and range, repeatability, intermediate precision, accuracy, durability and stability of this method, the results all meet the relevant requirements of the 2020 edition of the Chinese Pharmacopoeia.

[0034] (2) In the method for detecting the content of poloxamer 407 provided by the present invention, other components (such as sodium alginate in the embolic agent) do not interfere with the determination of the content of poloxamer 407, and the method is effective, stable and reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 The chromatogram of the test solution in Example 1.

[0036] Figure 2 This is the chromatogram of the blank solution under item "4.2" of the effect example.

[0037] Figure 3 This is the chromatogram of the system suitability solution under item "4.2" of the effect example.

[0038] Figure 4 It is the chromatogram of the mixed solution in Comparative Example 1.

[0039] Figure 5 It is the chromatogram of the mixed solution in Comparative Example 2.

[0040] Among them, 1 is poloxamer 407 and 2 is sodium alginate. DETAILED DESCRIPTION

[0041] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0042] In the following examples, poloxamer was purchased from BASF; batch number: GNF09421B; model number: 407; content, calculated as 100%).

[0043] In the following examples, sodium alginate was purchased from Qingdao Mingyue Alginate Tissue Engineering Materials Co., Ltd.; batch number: U01211201; content: 100% based on alginate.

[0044] In the following examples, the embolic agent was prepared by referring to Example 8 in patent CN106994117A, except that 250 mg of mitoxantrone hydrochloride (MIT) was not added, that is, MIT was not encapsulated; specifically, 25% (w / w) F-127 (poloxamer) and 0.5% (w / v) SA (sodium alginate) were added to purified water for dissolution, and freeze-dried to obtain a dry gel.

[0045] Example 1

[0046] 1. Solution preparation

[0047] Blank solution: water.

[0048] Reference solution: Take about 50 mg of poloxamer reference substance, dissolve and dilute with water to prepare a reference solution with a poloxamer concentration of about 1.0 mg / mL.

[0049] Linear series solution A: Accurately weigh about 50 mg of poloxamer reference substance, place in a 10 mL volumetric flask, add water to dissolve by ultrasonication and dilute to the mark, shake well, and use as linear stock solution (5 mg / mL). Sequentially measure 1.6 mL, 2.0 mL, and 2.4 mL of linear stock solution, place in 10 mL volumetric flasks, dilute to the mark with water, and obtain linear series solution A with poloxamer concentrations of about 0.8 mg / mL, 1.0 mg / mL, and 1.2 mg / mL.

[0050] System suitability solution: Take about 50 mg of poloxamer reference substance, accurately weigh it, place it in a 50 mL volumetric flask, add water to dissolve and dilute it to obtain a system suitability solution with a poloxamer concentration of about 1.0 mg / mL.

[0051] Sodium alginate localizing solution: Take about 20 mg of sodium alginate reference substance, place it in a volumetric bottle, add water to dissolve and dilute to obtain a solution containing sodium alginate at a concentration of about 20 μg / mL.

[0052] Test solution: Take 5 bottles of embolic agent (of which the labeled amount of poloxamer is 475 mg / bottle), transfer the test sample in the vial to a 500mL volumetric flask, add diluent to dissolve by ultrasonication, and dilute to the mark as the test sample stock solution; accurately measure 5mL of the test sample stock solution and place it in a 25mL volumetric flask, dilute to the mark with diluent, shake well, and prepare a test solution with a poloxamer concentration of approximately 1.0 mg / mL.

[0053] The preparation method is as above, but in the following actual experiments, the concentration is based on the actual quantitative calculation.

[0054] 2. Liquid chromatography conditions

[0055] A Shodex OHpak SB-804HQ column (8×300 mm, 10 μm) was used, the column temperature was 25°C, the ELSD detector, and the detector drift tube temperature was 50°C.

[0056] The mobile phase was 100 mmol / L ammonium formate aqueous solution, the flow rate was 0.5 mL / min, the elution time was 30 minutes, and the injection volume was 10 μL.

[0057] 3. Liquid phase detection

[0058] 3.1 Linear Equations

[0059] The linear series solution A was injected, and the linear equation was y=1.9326x+0.5495, where x was the logarithmic value of the concentration (μg / mL), y was the logarithmic value of the peak area, and the linear correlation coefficient r was 0.9999.

[0060] 3.2. Detection of poloxamer concentration in the test solution

[0061] The test solution was tested according to the above liquid chromatography conditions. Figure 1 As shown, the poloxamer peak area is 2183310, the retention time of poloxamer is 17.539min, and sodium alginate does not interfere with the poloxamer peak, and the separation degree is 2.83. The concentration of poloxamer in the test solution is 0.99038mg / mL calculated by the linear equation. According to the formula:

[0062]

[0063] Among them, C spl : The concentration of poloxamer in the test solution, mg / mL;

[0064] V spl : dilution volume of the test solution, mL;

[0065] W spl : The labeled amount of poloxamer in the test product (475 mg / bottle);

[0066] The calculated content of poloxamer in the test solution was 104.25%.

[0067] Effect Example Methodology Verification and Results

[0068] The results of specificity, system suitability, limit of quantitation, linearity and range, repeatability, intermediate precision, accuracy, durability and stability were used to verify whether the above detection methods met the requirements.

[0069] 4. Specificity and system applicability

[0070] 4.1 Solution preparation

[0071] See Example 1.

[0072] 4.2 Test results

[0073] Take a blank solution and inject it according to the above HPLC conditions. Figure 2 The results show that the blank solution (water) does not interfere with the elution of poloxamer.

[0074] Take the system suitability solution and inject it according to the above HPLC conditions. Figure 3The results showed that the retention time of poloxamer was 17.663 min and the peak shape was good.

[0075] The reference solution was taken and injected 6 times continuously under the above-mentioned liquid chromatography conditions to perform precision test. The results are shown in Table 1 below.

[0076] Table 1

[0077] name Peak area STD1-1 3118143 STD1-2 3250608 STD1-3 3325151 STD1-4 3321975 STD1-5 3286136 STD1-6 3322871 average value 3270814 RSD 2.5%

[0078] Then take the linear series solution A and, according to the above liquid chromatography conditions, obtain the linear results as shown in Table 2.

[0079] Table 2

[0080]

[0081] As shown in Tables 1 and 2, the peak area RSD value of poloxamer is 2.5%; within the concentration range of 788.8000 to 1183.2000 μg / mL, the linear equation of poloxamer is: y=1.9802x+0.5632, where x is the logarithmic value of the concentration (μg / mL), and y is the logarithmic value of the peak area; and the linear correlation coefficient r is 1.0000. The above results show that the detection method of the present invention meets the requirements of specificity and system applicability.

[0082] 5. Limit of Quantitation

[0083] 5.1 Solution preparation

[0084] Quantitative limit solution: The quantitative limit is determined by the conventional method in the art, generally at the corresponding concentration or the amount injected into the instrument when the signal-to-noise ratio is 10:1; S / N is greater than 10 or more. Specifically, 3 mL of the reference solution is accurately measured, placed in a 10 mL volumetric bottle, diluted with water, fixed to volume, and shaken to obtain the quantitative limit solution, the poloxamer concentration of which is about 0.3 mg / mL.

[0085] 5.2 Test results

[0086] The quantitative limit solution was taken and tested 6 times in succession under the above-mentioned liquid chromatography conditions. The results are shown in Table 3 below.

[0087] Table 3

[0088]

[0089] From the above results, it can be seen that the concentration of the quantitative limit solution is 298.14 μg / mL (30% of the concentration level of the test solution), the signal-to-noise ratio S / N of the 6-shot quantitative limit solution is ≥10, and the peak area RSD of poloxamer is 3.9%, indicating that the detection method of the present invention meets the quantitative limit requirements.

[0090] 6. Linearity and Range

[0091] 6.1 Solution preparation

[0092] Linear series solution B: Accurately weigh 50 mg of poloxamer reference substance, place it in a 10 mL volumetric flask, add water to dissolve by ultrasonic and dilute to the scale, shake well, and use it as the linear stock solution (5 mg / mL). Sequentially measure 0.5 mL, 0.8 mL, 1.0 mL, 1.2 mL, and 1.5 mL of the linear stock solution, place them in 5 mL volumetric flasks, dilute to the scale with water, and obtain a linear series solution B with a poloxamer concentration of approximately 0.5 mg / mL, 0.8 mg / mL, 1.0 mg / mL, 1.2 mg / mL, and 1.5 mg / mL.

[0093] 6.2 Test results

[0094] Take linear series solution B and, according to the above liquid chromatography conditions, obtain the linear results shown in Table 4.

[0095] Table 4

[0096]

[0097] As shown in Table 4, the linear equation of poloxamer in the concentration range of 493.0000 to 1479.0000 μg / mL is: y=1.9915x+0.519, wherein x is the logarithmic value of the concentration (μg / mL), and y is the logarithmic value of the peak area; the linear correlation coefficient r is 0.9992, which is greater than 0.999, and the linear relationship is good, indicating that the detection method of the present invention meets the linear requirements.

[0098] 7. Repeatability

[0099] 7.1 Solution preparation

[0100] Repeatable solution: Take 5 bottles of embolic agent, transfer the test sample in the bottles to a suitable volumetric bottle, dissolve and dilute with water to make a solution with a poloxamer concentration of about 1.0 mg / mL, shake well, and transfer 6 portions in parallel.

[0101] 7.2 Test results

[0102] Take the above 6 repetitive solutions, inject them respectively according to the above liquid chromatography conditions, obtain the peak area, and then calculate the concentration according to the linear equation "y = 1.9802x + 0.5632" obtained in "4.2", and then obtain the content according to the theoretical concentration (475*5) / 500*5 / 25 = 0.95 mg / mL. The results are shown in Table 5.

[0103] Table 5

[0104]

[0105] As shown in Table 5, the RSD of the content values ​​of the 6 repeatable solutions is 1.0%, indicating that the repeatability of the method of the present invention meets the detection requirements.

[0106] 8. Accuracy

[0107] 8.1 Solution preparation

[0108] Recovery solution: Accurately weigh appropriate amounts of poloxamer, place in a volumetric flask containing 20 mg of sodium alginate, add water to dissolve and dilute to prepare mixed solutions containing approximately 0.8 mg, 1.0 mg, and 1.2 mg of poloxamer per 1 mL. Prepare 3 copies of each concentration in parallel.

[0109] 8.2 Test results

[0110] Take the above recovery solution, inject it according to the above liquid chromatography conditions, obtain the peak area, and then obtain the calculated amount of poloxamer according to the linear equation "y = 1.9802x + 0.5632" obtained in item "4.2". According to "recovery = calculated amount / added amount", the results are shown in Table 6.

[0111] Table 6

[0112]

[0113] As can be seen from the above table, the average recoveries at low, medium and high concentration levels are 100.8%, 101.5% and 101.5% respectively, and the RSD of the recoveries is 0.8% (n=9), indicating that the accuracy of the method of the present invention meets the detection requirements.

[0114] 9. Intermediate precision

[0115] 9.1 Solution preparation

[0116] Linear series solution C: Accurately weigh 50 mg of poloxamer reference substance, place it in a 10 mL volumetric flask, add water to dissolve by ultrasonication and dilute to the scale, shake well, and use it as the linear stock solution (5 mg / mL). Sequentially measure 0.8 mL, 1.0 mL, and 1.2 mL of the linear stock solution, place them in 5 mL volumetric flasks, dilute to the scale with water, and obtain a linear series solution C with a poloxamer concentration of approximately 0.8 mg / mL, 1.0 mg / mL, and 1.2 mg / mL.

[0117] Intermediate precision solution: Take 5 bottles of embolic agent, transfer the test sample in the bottles to a suitable volumetric bottle, dissolve and dilute with water to make a solution with a poloxamer concentration of about 1.0 mg / mL, shake well. Take 6 portions in parallel.

[0118] 9.2 Test results

[0119] Take linear series solution C and, according to the above liquid chromatography conditions, obtain the linear equation y=1.9015x+0.7575, where x is the logarithmic value of concentration (μg / mL) and y is the logarithmic value of peak area.

[0120] Take the above 6 portions of intermediate precision solution, inject them respectively according to the above liquid chromatography conditions, obtain the peak area, calculate the concentration according to the above linear equation, and then obtain the content according to the theoretical concentration (475*5) / 500*5 / 25=0.95 mg / mL. The results are shown in Table 7.

[0121] Table 7

[0122]

[0123] It can be seen from the above table that the RSD of the content values ​​of the 6 intermediate precision solutions is 0.8%; according to item "7", the RSD of the content values ​​of the 6 repeatability solutions is 1.0%, and the RSD of the average content value is 0.9%, indicating that the method of the present invention meets the precision detection requirements.

[0124] 10. Durability

[0125] 10.1 Solution preparation

[0126] See Example 1 and the reproducible solution under "7.1".

[0127] 10.2 Test results

[0128] Based on the liquid chromatography conditions in item "2", the flow rate, drift tube temperature and salt concentration were adjusted, and repeatable solution injection was performed for detection. The results are shown in Table 8.

[0129] Table 8

[0130]

[0131] It can be seen from the above table that the solution content under each change condition is in the range of 100.9-106.3%, and the RSD is in the range of 1-2%, indicating that the durability of the method in the present invention meets the detection requirements.

[0132] 11. Stability

[0133] 11.1 Solution preparation

[0134] See Example 1.

[0135] 11.2 Test results

[0136] The test solution was taken at different times and according to the above liquid chromatography conditions. The injection results are shown in Table 9.

[0137] Table 9

[0138] Time (h) Peak area Peak area ratio to 0h (%) 0 2887523 N / A 4 2984551 103 8 3015010 104 10 3041308 105 19 3091813 107 29 3108187 108 63 3142260 109

[0139] As shown in Table 9, the ratio of the peak area of ​​poloxamer at each time point to that at 0 h is in the range of 103-109% (unified sequence). The above results show that the test solution is stable when placed at room temperature for 63 h.

[0140] The validation summary of the above methodology is shown in Table 10 as follows:

[0141] Table 10

[0142]

[0143]

[0144]

[0145] It can be seen that the detection method described in the present invention has good specificity, accuracy and durability, and meets the detection requirements of this product.

[0146] Comparative Example 1

[0147] The samples and treatment methods of Comparative Example 1 are basically the same as those of Example 1, except that the mobile phases are: 2% formic acid solution as mobile phase A and methanol as mobile phase B.

[0148] The elution gradient is shown in Table 11 below:

[0149] Table 11

[0150] Time (min) Mobile phase A (%) Mobile phase B (%) 0 65 35 5 65 35 10 20 80 15 20 80 15.1 65 35 20 65 35

[0151] Test results: Figure 4 As shown in the figure, the poloxamer chromatographic peak has obvious tailing and the asymmetry is 1.74. According to the peak area, it can be judged that due to the low content of sodium alginate, the peak area should be small. Figure 4 The peak area of ​​the other peak that appears in the graph is larger, so it is known that it is the solvent peak, and the sodium alginate peak is enclosed by the poloxamer peak. The results show that the detection method of Comparative Example 1 cannot accurately determine the content of poloxamer 407 in the thermosensitive embolic agent, and the separation degree between sodium alginate and poloxamer is poor, and it is difficult to separate the sodium alginate chromatographic peak.

[0152] Comparative Example 2

[0153] The samples and treatment methods of Comparative Example 2 are basically the same as those of Example 1, except that the mobile phases are: 100 mmol / L ammonium formate aqueous solution as mobile phase A, and methanol as mobile phase B.

[0154] The elution gradient is shown in Table 12 below:

[0155] Table 12

[0156] Time (min) Mobile phase A (%) Mobile phase B (%) 0 65 35 5 65 35 10 20 80 15 20 80 15.1 65 35 20 65 35

[0157] Test results: Figure 5 As shown, the poloxamer chromatographic peak has a certain degree of front extension, and the asymmetry is 1.39; Figure 4 The results show that the detection method of Comparative Example 2 cannot accurately determine the content of poloxamer 407 in the thermosensitive embolic agent, and it is difficult to separate the chromatographic peak of sodium alginate.

[0158] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0159] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A method for detecting the content of poloxamer 407, characterized in that: The method comprises the following steps: detecting the sample solution to be tested by high performance liquid chromatography and calculating the content; Wherein, the sample solution to be tested contains poloxamer 407; In the high performance liquid chromatography method: the chromatographic column is a gel chromatographic column, an isocratic elution method is adopted; and the mobile phase is an ammonium formate aqueous solution.

2. The method for detecting the content of poloxamer 407 as claimed in claim 1, characterized in that: The concentration of poloxamer 407 in the sample solution to be tested is 0.5-1.5 mg / mL; And / or, the sample solution to be tested is prepared by dissolving the component to be tested in a diluent.

3. The method for detecting the content of poloxamer 407 as claimed in claim 2, characterized in that: The component to be tested is an embolic agent, and the embolic agent also includes sodium alginate.

4. The method for detecting the content of poloxamer 407 as claimed in claim 3, characterized in that: In the embolic agent, the mass ratio of poloxamer 407 to sodium alginate is (10-35):(0-1).

5. The method for detecting the content of poloxamer 407 as claimed in claim 2, characterized in that: The diluent is water.

6. The method for detecting the content of poloxamer 407 as claimed in claim 1, characterized in that: In the high performance liquid chromatography, the flow rate of the mobile phase is 0.25 to 0.75 mL / min; And / or, in the high performance liquid chromatography method, the concentration of ammonium formate in the ammonium formate aqueous solution is 95 to 105 mmol / L.

7. The method for detecting the content of poloxamer 407 as claimed in claim 1, characterized in that: The injection volume of the high performance liquid chromatography method is 5 to 20 μL; And / or, in the high performance liquid chromatography, the particle size of the filler in the chromatographic column is 8 to 12 μm; And / or, in the high performance liquid chromatography, the column temperature is 20 to 30°C; And / or, in the high performance liquid chromatography, the chromatographic column is a Shodex OHpak SB-804HQ chromatographic column; And / or, in the high performance liquid chromatography, the length of the chromatographic column is 200 to 500 mm; And / or, in the high performance liquid chromatography, the inner diameter of the chromatographic column is 5 to 10 mm.

8. The method for detecting the content of poloxamer 407 as claimed in claim 1, characterized in that: In the high performance liquid chromatography, the detector is an evaporative light scattering detector; And / or, in the high performance liquid chromatography, the temperature of the drift tube in the detector is 48-52°C.

9. The method for detecting the content of poloxamer 407 as claimed in claim 1, characterized in that: The content is determined by the standard curve method.

10. The method for detecting the content of poloxamer 407 according to claim 9, characterized in that: The linear equation obtained by the standard curve method is "y=1.9326x+0.5495, r=0.9999", "y=1.9802x+0.5632, r=1.0000" or "y=1.9915x+0.519, r=0.9992", wherein x is the logarithmic value of the concentration in μg / mL and y is the logarithmic value of the peak area.

Citation Information

Cited By

  • Method for detecting content of poloxamer 188 in human erythropoietin injection

    CN122306982A